YLL545
Product Specifications
UNSPSC Description
YLL545 is a type of vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor. YLL545 can inhibit VEGF-induced phosphorylation of VEGFR2 and the activation of downstream signaling factors (like phosphorylated STAT3 and phosphorylated ERK1/2) in human umbilical vein endothelial cells (HUVEC). YLL545 can suppress the proliferation, migration, invasion, and angiogenesis of HUVEC. YLL545 can induce apoptosis in breast cancer mice and inhibit tumor growth[1].
Target Antigen
Apoptosis; ERK; STAT; VEGFR
Type
Reference compound
Related Pathways
Apoptosis;JAK/STAT Signaling;MAPK/ERK Pathway;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/yll545.html
Smiles
O=C(NC1=CC=CC(C(F)(F)F)=C1)NC2=CC=C(OC3=C4C(NN=C4)=NC=N3)C=C2
Molecular Weight
414.34
References & Citations
[1]Zhang J, et al. The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer. Oncotarget. 2016 Jul 5;7(27):41067-41080.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-164551/YLL545-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-164551/
Clinical Information
No Development Reported
CAS Number
1423126-69-5
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
![6-Oxabicyclo[3.2.1]oct-3-en-7-one](https://cdn.genprice.uk/genprice/genprice2.png)
![6-Oxabicyclo[3.2.1]oct-3-en-7-one](https://cdn.genprice.uk/genprice/genprice4.png)
![6-Oxabicyclo[3.2.1]oct-3-en-7-one](https://cdn.genprice.uk/genprice/genprice3.png)
